Product Description
Dydrogesterone is an orally active progestogen which acts directly on the uterus, producing a complete secretory endometrium in an estrogen-primed uterus. At therapeutic levels, dydrogesterone has no contraceptive effect as it does not inhibit or interfere with ovulation or the corpus luteum. Furthermore, dydrogesterone is non-androgenic, non-estrogenic, non-corticoid, non-anabolic and is not excreted as pregnanediol. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Dydrogesterone#section=Pharmacology-and-Biochemistry)
Mechanisms of Action: PR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Abbott Laboratories
Company Location: ABBOTT PARK IL 60064-3500
Company CEO: Robert B. Ford
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Menopause|Infertility, Male|Infertility, Female|Myofibroma|Abortion, Spontaneous|Pregnancy Outcomes|Leiomyoma|Genital Diseases, Female|Abortion, Threatened|Obstetric Labor, Premature|Abortion, Habitual|Multiple Sclerosis|Gynatresia|Embryo Loss|Fetal Death|Endometrial Cancer|Infertility
Phase 3: Infertility, Male|Infertility, Female|Menopause|Obstetric Labor, Premature|Abortion, Habitual|Abortion, Threatened|Abortion, Spontaneous|Bone Cancer|Endometrial Cancer|Anal Cancer|Kidney Diseases|Uterine Cancer|Weight Loss|Infertility|Weight Gain|Pregnancy Outcomes|Vascular Cancer|Liver Cancer|Pelvic Cancer|Vitamin A Deficiency|Follicular Cyst|Hypertension, Renal|Drug Overdose|Stroke|Vaginal Cancer|Protein Deficiency|Body Weight Changes|Genital Cancer, Female|Pregnancy, Abdominal|Pregnancy, Ovarian|Ovarian Cysts|Muscle Cancer|Acute Respiratory Distress Syndrome|Male Breast Cancer
Phase 2: Anorexia
Phase 1: Pregnancy, Ovarian|Hyperandrogenism|Ovarian Cysts|Follicular Cyst|Conduct Disorder|Polycystic Ovary Syndrome|Infertility|Pregnancy Outcomes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Study on the efficacy of different MHT protocols in intervening with cognitive function in perimenopausal and postmenopausal women based on fNIRS detection | N/A |
Not yet recruiting |
Unknown |
2029-12-01 |
|
| ChiCTR2400094539 | N/A |
Not yet recruiting |
Unknown |
2027-12-31 |
|
| 2023-509919-89-00 | P4 |
Unknown Status |
Infertility, Male|Infertility, Female |
2027-10-01 |
|
| ChiCTR2400091369 | N/A |
Not yet recruiting |
Injuries/wounds Unspecified |
2027-06-30 |